Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
about
Renal effects of dapagliflozin in patients with type 2 diabetesThe clinical application of linagliptin in AsiansThe Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney DiseaseBeat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agentsSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewDapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion InjuryEffects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemThe effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin.The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 DiabetesCofilin1 is involved in hypertension-induced renal damage via the regulation of NF-κB in renal tubular epithelial cells.Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.New therapeutic agents in diabetic nephropathy.The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.The renal effects of SGLT2 inhibitors and a mini-review of the literature.Tubulointerstitial disease in diabetic nephropathy.Sodium-glucose cotransport.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.Diabetic nephropathy: landmark clinical trials and tribulations.A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.New and old agents in the management of diabetic nephropathy.SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.Targeting inflammation in diabetic kidney disease: early clinical trials.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Distribution of glucose transporters in renal diseases.Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice
P2860
Q24564811-9DB043E4-D55D-4462-B830-04465831102BQ26781942-6DF4B1B6-C640-4B02-9737-DC8B3FD7AEEEQ26784454-8C2FDDF6-444F-475A-A5B5-CD05F33E7EE2Q27010669-DED53F2A-03A1-4270-AB90-E020171857B7Q28079134-FEDA95BB-01DE-4733-9D2E-176A9CB905A2Q28552482-90F820DD-9EDC-4CCA-BA89-0F1B2CDD201AQ32186373-0DE96E52-8DA1-4DAF-9476-B2F49C15DB53Q33696974-AE72694D-F4FB-45FC-947A-1664D38E0E10Q34062829-0EF69A09-A18F-4C2F-AB7B-E0191D84FAEBQ34503796-01A1AD3D-0FA1-4D3A-8C78-124E753EA1CDQ35181821-D7C391AE-A3B9-4BFF-BD22-5EB43255EAABQ35392355-E4D2F4CE-8ED3-40D5-A7EE-C4AC1B66CDFBQ35824459-1E0381DB-0A8B-4B14-B3D0-AD756107E12FQ35951020-B0673624-77C2-45EF-9FB4-67585FF8219BQ36142616-C5BCB6AB-5089-41CF-92B2-38747FF73FBFQ36851156-0368E1DE-C323-48B6-AB1E-AF63EBD82535Q36937697-12AC09A6-C38C-49E5-A4F3-8D6C7BA71310Q37219076-58A7A775-F966-4717-9A53-6FBFF0D45131Q37559164-4DE987EE-BEB3-4FE5-83FC-2581AAB13B9BQ37559421-C3F310A1-5908-4284-8006-5EBAB9D3D828Q37632127-23C9F7EF-DF2B-466C-8661-4A250397352AQ37669397-0590AD61-3793-42AE-B5EB-BE91321682DAQ37718851-44732000-B9E1-4DB3-A1BB-88389D805D3FQ38130748-A3A8B7FF-EFDE-4EE4-A6C1-E5B6CF4F6B1FQ38330456-1B030804-3B20-4BA8-AC4F-24E9ED0D22F7Q38338539-5254135E-F1A3-46DB-92A0-F269DA0AAC83Q38537119-A7FFA284-2E57-454F-B11B-E00080D8CC63Q38635763-8625F4B2-E1F1-462C-9135-B0E576E5481AQ38667712-21CF7EA5-B086-4C1B-9B50-BE0729E2EDA4Q38715153-BD577794-B2A5-450A-9835-34209F9C32A7Q38738871-EF19BCA7-2E25-4D47-82CC-3AA9A9AFAA31Q38775305-93073C2A-7BB8-4D9B-B710-25CC6A52697CQ38857166-C4A355E7-8605-4C10-ABEC-5F2C870BF282Q38936746-7AF76B87-83A3-4A07-A872-57759FF06E58Q38961637-3B0AF6EC-FFCF-4F55-A165-3BDD52A23E21Q39000587-E7F05ED5-A874-4B0A-A832-A5DDC482A78EQ39170860-4EC281D4-02C2-4996-96E9-7C7D5502F1C8Q39290337-7C532ADF-6F9F-4693-A683-B95F046931A3Q41570521-0D2B0D47-683E-4CD3-B70B-723F8C9DEC28Q42329981-053FB32B-A053-48F2-83A9-29E755F8C79E
P2860
Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?
@ast
Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?
@en
Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?
@nl
type
label
Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?
@ast
Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?
@en
Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?
@nl
prefLabel
Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?
@ast
Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?
@en
Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?
@nl
P2093
P2860
P1433
P1476
Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?
@en
P2093
Amanda Mather
Carol Pollock
Harshini Mudaliar
Simon Gross
Usha Panchapakesan
P2860
P304
P356
10.1371/JOURNAL.PONE.0054442
P407
P577
2013-02-04T00:00:00Z